The U.S. Food and Drug Administration granted accelerated approval to GSK's once-daily oral treatment neladalkib, marketed as Nelkarmi, for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer whose disease progressed after ALK tyrosine kinase inhibitor treatment. The approval is based on tumor-response evidence, including responses in patients with brain metastases, rather than a demonstrated overall survival advantage. Neladalkib was acquired through GSK's $10.6 billion purchase of Nuvalent, completed in July 2026, and is the second acquired lung cancer asset to receive FDA approval. A late-stage trial is evaluating neladalkib against Roche's Alecensa in first-line treatment.
Reuters
Why it matters strategically
GSK has secured two regulatory milestones from a substantial oncology acquisition, but approval alone does not establish that the transaction will generate an adequate return.
The value of the acquisition depends on market penetration, treatment sequencing, confirmatory evidence, and potential expansion into earlier treatment lines.